Skip to main content
. 2019 Sep 23;5(2):e001013. doi: 10.1136/rmdopen-2019-001013

Figure 1.

Figure 1

Identification of biologic/targeted synthetic disease-modifying antirheumatic drug (b/tsDMARD) switchers, first b/tsDMARD users and conventional synthetic DMARD users during the study period. Note: the first treatment after the diagnosis of rheumatoid arthritis that met the definition of treatment group and during the study period (2007–2017) was used to define the treatment group.